Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut

Trial Profile

Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2018

At a glance

  • Drugs Peanut allergy immunotherapy (Primary)
  • Indications Peanut hypersensitivity
  • Focus Therapeutic Use
  • Acronyms OLFUS-VIPES
  • Sponsors DBV Technologies
  • Most Recent Events

    • 29 May 2018 Results presented in the DBV Technologies media release.
    • 29 May 2018 Data from this trial were presented at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting, according to a DBV Technologies media release.
    • 08 May 2018 Data from this trial will be presented at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting, according to a DBV Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top